Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
PHC Group develops, manufactures, sells, and services across diabetes management, diagnostics and life sciences, as well as healthcare service businesses. Committed to its corporate mission, “We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people,” the company offers value-added products and services to customers in over 125 countries.
Epredia is a global precision cancer diagnostics company working to improve patient outcomes by providing groundbreaking technologies. Since our humble beginnings in 1937, every product developed has been impacted by generations of employees who are committed to improving lives by enabling pathologists through enhancing precision cancer diagnostics
Lonza Bioscience Solutions provides life science researchers with the tools they need to develop and test therapeutics, from basic research to final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software for biomanufacturing. Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and government research institutions. Primary brands include Clonetics™ Primary Cells, BioWhittaker™ Media, RAFT™ 3D Cell Culture System, Nucleofector™ Transfection Technology, MycoAlert™ Mycoplasma Detection Assay, PyroGENE™ rFC Endotoxin Detection Assay, PyroTec™ PRO Robotic Solution and WinKQCL™ Endotoxin Testing Analysis Software, MODA™ Environmental Monitoring Solutions.
We are a target discovery and gene editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno oncology.
Our proprietary AI target discovery engine is called “Diamond.”
Diamond is AI big data science meeting target identification, dramatically compressing man years and billions of drug development dollars to develop a live drug.
Our first product is Alexis-Pro and Alexis-ISO, off-the-shelf allogenic chPD1, and iso-mesothelin CAR-T(s) for solid tumor.
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.
Veracyte is a global diagnostics company that improves patient care by informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our extensive biorepositories, immuno-oncology biomarker testing and analytical services help our biopharmaceutical partners to advance their therapeutic discovery, development and commercialization programs.
Metabolon, Inc., reveals biological insights otherwise unseen. Over nearly two decades, Metabolon has built the best metabolomic competency in the world. Today, Metabolon enables, accelerates and supports drug development through biomarker discovery, understanding mechanism of action, patient stratification, and more, as evidenced by >2,000 publications, numerous high-impact case studies and customer testimonials.
Metabolon’s scalable, customizable metabolomics solutions support discovery through clinical trials and product life-cycle management. Metabolon’s diverse patient data set is equipped to deliver biologically relevant insights to address some of the most challenging and pressing questions in the life sciences. Metabolon is ISO 9001:2015 certified for analytical and diagnostic testing of biological specimens, certified by CLIA and accredited by the College of American Pathologists for diagnostic testing on human specimens. The company, founded in 2000, is based in Research Triangle Park, North Carolina. For more information, please visit www.metabolon.com
Champions Oncology provides an end-to-end range of research and development solutions and services, from cell lines to modeling treatment in the clinic using PDX models, that improve the productivity of oncology drug development. Using both in vitro and in vivo testing platforms, companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.
Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX.
Concept Life Sciences (a Malvern Panalytical brand) is an expert contract research organisation delivering ‘best-in-class’ solutions and cutting-edge technology with uncompromising quality. Our immunology expertise was grown from Aquila BioMedical we continue our open, science-led and consultative approach to offer world-leading Immunology research services. We use our extensive expertise across multiple therapeutic areas to deliver highly specialist solutions and innovative models to the heart of drug discovery and development. Whether your program is small molecule, biologics, gene or cellular therapy we can provide support with an interdisciplinary team of scientists to answer your specific scientific questions and challenges. We deliver a comprehensive platform of integrated solutions built on expert knowledge, collaboration, flexibility and extensive in-house resources ensuring the best route to clinic for your therapeutics
ANGLE is a liquid biopsy company focused on enrichment and analysis of circulating tumour cells (CTCs) from patient blood to enable non-invasive biomarker testing. Our patented Parsortix® system (RUO) captures a broad range of CTCs, including mesenchymal CTCs, and clusters.
ANGLE has GCLP laboratories in the UK and US offering a comprehensive BioPharma CTC enrichment and analysis services. ANGLE’s highly experienced assay development team would welcome discussing your clinical study biomarker requirements.
Committed to healthcare since 2004, LARVOL has been delivering custom intelligence solutions that provide healthcare and life sciences experts accurate, rapid, expertly-curated information to enable strategic decision-making. Specifically in the oncology space, we collate and simplify data from over 25,000 sources and offer novel tools to extract meaningful insights. Our newest product CLIN delivers the complete universe of immuno-oncology clinical trial data in one, easy-to-navigate platform. That's ten years of trial data, manually reviewed and coded to extract every table, graph, and figure. New data is added as it's released from publications, conferences, and guidelines.